){kind=logo}
Mitch Nussbaum, co-chair of Loeb & Loeb’s Capital Markets & Corporate department, and Capital Markets partner Janeane Ferrari are mentioned in a Law360 article for representing DiaCarta Ltd., a diagnostics company and infectious disease test developer, in a definitive business combination agreement with blank-check company HH&L Acquisition Co as part of a $460 million deal.
According to the article, the business combination has a pre-money equity value of $460 million and is expected to close in the first quarter of 2023. In addition, the deal would result in the California-based precision molecular diagnostics company becoming publicly traded on the Nasdaq Global Market.
According to the article, the business combination has a pre-money equity value of $460 million and is expected to close in the first quarter of 2023. In addition, the deal would result in the California-based precision molecular diagnostics company becoming publicly traded on the Nasdaq Global Market.
Click here to read the full article on Law360 (subscription required).
-
Co-Chair, Loeb & Loeb LLP -
Partner